Recombinant Human Cathepsin K

• Cat.No.: CTSK-1659H
• Product Overview: Recombinant human CTSK is a 35.1 kDa homodimeric protein consisting of 99 amino acid polypeptide domain.

Specification

• Cat. No.: CTSK-1659H
• Description: CTSK is a member of the papain cysteine proteinase family and has been identified as the predominant proteinase responsible for the resorption of the bone matrix. The enzyme cleaves proteins such as collagen type I, collagen type II and osteonectin and therefore plays a role in bone remodeling and resorption in diseases such as osteoporosis, osteolytic bone metastasis and rheumatoid arthritis.
• Molecular Weight: 35.1 kDa
• Source: E. Coli
• Species: Human
• Form: Liquid (25 mM Tris pH 8.0, 500 mM NaCl).
• Appearance: Liquid
• Purity: ≥95% by SDS-PAGE
• Storage: Procathepsin K can be aliquoted and stored at -80°C. Repeated freeze-thaw cycles must be avoided.
• Tag: Non

Gene Information

• Gene Name: CTSK cathepsin K [ Homo sapiens ]
• Official Symbol: CTSK
• Synonyms: CTSK; cathepsin K; CTSO; PKND; PYCD; CTS02; CTSO1; CTSO2; MGC23107; cathepsin K; cathepsin O; cathepsin X; cathepsin O1; cathepsin O2; OTTHUMP00000032938
• Gene ID: 1513
• mRNA Refseq: NM_000396
• Protein Refseq: NP_000387
• MIM: 601105
• UniProt ID: P43235
• Chromosome Location: 1q21
• Pathway: Lysosome; Osteoclast Signaling; Osteoclast differentiation; Rheumatoid arthritis; Toll-like receptor signaling pathway
• Function: cysteine-type endopeptidase activity; cysteine-type peptidase activity; peptidase activity

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.